False economy? Second report - The total economic cost of high rebates on NHS medicines – further analysis and sensitivity testing

WPI now extend the analysis beyond the narrow financial terms in the first report, calculating the total economic benefit that could be expected across different Payment Rates. In addition, WPI conduct sensitivity analysis to test what total economic benefit would be in the event that the survey projections for life sciences R&D investment under higher Payment Rates prove too pessimistic.